Skip to main content
B

BrightPath Biotherapeutics Co., Ltd. — Investor Relations & Filings

Ticker · 4594 ISIN · JP3274140007 T Manufacturing
Open in API
Filings indexed 69 across all filing types
Latest filing 2024-02-09 Interim / Quarterly Rep…
Country JP Japan
Listing T 4594

About BrightPath Biotherapeutics Co., Ltd.

https://www.brightpathbio.com/english/

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company's core technology is its iPS-NKT platform, a novel allogeneic cell therapy that utilizes induced pluripotent stem cells (iPSCs) to produce large, homogeneous quantities of natural killer T (NKT) cells for cancer treatment. This proprietary approach is designed to overcome the natural scarcity of NKT cells, enabling the therapeutic application of their multifaceted anti-tumor effects. In addition to its cell therapy program, the company's development pipeline includes cancer peptide vaccines and immuno-modulating antibodies.

Recent filings

Filing Released Lang Actions
四半期報告書－第21期第3四半期(2023/10/01－2023/12/31)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) filed by BrightPath Biotherapeutics Co., Ltd. in accordance with the Financial Instruments and Exchange Act of Japan. It contains detailed financial statements, management's analysis of financial conditions and results of operations, and information regarding shareholdings and stock options for the third quarter of the 21st fiscal period (covering October 1, 2023, to December 31, 2023). This fits the definition of an Interim/Quarterly Report (IR). Q3 21
2024-02-09 Japanese
訂正有価証券届出書（組込方式）
Capital/Financing Update Classification · 1% confidence The document is titled "有価証券届出書" (Securities Registration Statement) and is filed with the "関東財務局長" (Kanto Local Finance Bureau Director). It specifically details the terms for the offering of "新株予約権証券" (Stock Acquisition Rights Certificates), including issuance price, exercise price, number of shares, and capital structure implications. This structure and content strongly indicate a regulatory filing related to the issuance of securities, which aligns with the definition of a registration statement or prospectus for a capital raising event. Given the options, this is a filing related to capital/financing activities, but the document itself is the formal registration statement, not just a simple announcement. In the context of Japanese filings, a "有価証券届出書" is a comprehensive disclosure document. Since the document details the terms of a new share warrant offering (a form of capital raising), the most appropriate code is CAP (Capital/Financing Update), as it is the core document detailing the financing terms. While it is a formal regulatory filing, CAP is more specific than RNS or LTR for this content. It is not a 10-K (Annual Report), IR (Interim Report), or ER (Earnings Release). It is the primary disclosure for the financing event.
2023-11-15 Japanese
有価証券届出書（組込方式）
Capital/Financing Update Classification · 1% confidence The document is a formal Japanese regulatory filing, indicated by headers like "【提出書類】有価証券届出書" (Filing Document: Securities Registration Statement) and submission details to the "関東財務局長" (Kanto Local Finance Bureau Director). The content details the terms of issuing "新株予約権証券" (Stock Acquisition Rights Certificates), including issuance price, exercise price adjustments, and the purpose of fundraising (developing cancer immunotherapy drugs). This structure and content strongly align with a filing related to the issuance of securities or capital changes. Among the provided codes, "CAP" (Capital/Financing Update) is the most appropriate fit for a detailed registration statement concerning the issuance of stock acquisition rights (warrants) for fundraising purposes. While it is a formal filing, it is specifically about capital raising, making CAP more precise than the general fallback RNS.
2023-11-14 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act, specifically confirming the accuracy of a Quarterly Report (Shihanki Hokokusho). It is a regulatory filing required by Japanese law to accompany financial reports, confirming the validity of the contents by the CEO and CFO. Since it is a specific regulatory filing that does not fit into the primary financial report categories (like 10-K or IR) and is not a mere announcement of a report, it falls under the general Regulatory Filings category.
2023-11-10 Japanese
四半期報告書－第21期第2四半期(2023/07/01－2023/09/30)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau in Japan, pursuant to the Financial Instruments and Exchange Act. It contains detailed financial statements (balance sheets, etc.) for the second quarter of the 21st fiscal period (April 1, 2023, to September 30, 2023). As it is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data, it is classified as an Interim/Quarterly Report. H1 2024
2023-11-10 Japanese
確認書
Report Publication Announcement Classification · 1% confidence The document is a 'Confirmation Letter' (Kakunin-sho) filed under the Financial Instruments and Exchange Act in Japan. It specifically confirms the accuracy of the contents of a Quarterly Report (Shihanki Hokokusho) for the first quarter of the 21st fiscal period. Since this is a regulatory filing confirming the validity of a report rather than the report itself, and it does not fit into specific categories like 10-K or IR, it falls under the general regulatory filing category.
2023-08-10 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.